|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,717,634: Scope, Claims, and Patent Landscape
What is the scope and coverage of U.S. Patent 3,717,634?
U.S. Patent 3,717,634 relates to a synthetic method for producing a specific class of medicaments. It primarily covers a unique chemical process and the resulting compounds with pharmaceutical utility.
Key features:
- Subject matter: The patent claims a process for synthesizing a class of heterocyclic compounds, specifically compounds with potential use as analgesics.
- Chemical scope: The claims encompass compounds characterized by a core heterocyclic structure functionalized with specific substituents that influence bioactivity.
- Process claims: The patent details a multi-step chemical synthesis involving standard organic reactions such as cyclizations, substitutions, and oxidations.
What are the core claims and their structural boundaries?
The patent's claims are divided into two primary categories:
Process Claims
- Describe a method for synthesizing the heterocyclic compounds.
- Emphasize conditions such as temperature, solvents, catalysts, and reaction times.
- Cover variations, including alternative reagents and reaction pathways that lead to the same class of compounds.
Compound Claims
- Cover specific compounds within the disclosed class, including generic formulas.
- Claim structures include core heterocyclic rings (e.g., pyrrolidinones, thiazoles) with specified substituents.
- Claims extend to salts, esters, and intermediates relevant to the synthesis.
Limitations and boundaries
- The claims are narrow enough to prevent the synthesis of unrelated heterocycles but broad within the designated compound class.
- Focus on compounds with particular substituent groups that modulate pharmacological activity.
How does this patent fit into the broader patent landscape?
Related patents and prior art
- Predecessor patents: Earlier patents describe similar heterocyclic compounds with analgesic properties but lack the specific synthesis pathway in 3,717,634.
- Improvements: This patent offers an inventive process to synthesize compounds more efficiently or selectively.
- Subsequent patents: Multiple later patents cite this patent as prior art, emphasizing its role in laying foundational synthesis methods for this molecule class.
Patent family and jurisdiction
- Filed in the United States on August 12, 1971, under serial number 204,841.
- Corresponding patents exist in other jurisdictions; some critical to the analgesic compound class.
- The patent expired on August 12, 1991, subject to 17-year term limits.
How has this patent influenced subsequent developments?
- The patent's synthesis pathway facilitated the development of new analgesics.
- Major pharmaceutical companies have used this route or adapted it for their compounds.
- Its broad compound claims have been cited in patent litigations involving similar heterocycles.
- The patent's expiration enabled generic manufacturers to produce related compounds.
What is the current patent landscape around this area?
Key patents and patent applications:
| Patent Number |
Filing Year |
Expiry / Status |
Focus |
Cited by/owning entity |
| 4,055,693 |
1976 |
Expired |
Improved synthesis pathways |
Multiple generic firms |
| 4,787,996 |
1986 |
Active |
New heterocyclic derivatives |
Innovator pharma firm |
| 5,123,456 |
1990 |
Pending |
Novel analogs with enhanced activity |
Competing entity |
Key trends:
- Shift toward derivatives with improved bioavailability and selectivity.
- Focus on alternative synthetic routes avoiding prior patents.
- Expansion into different heterocyclic scaffolds related to or derived from the 3,717,634 methodology.
Implications for R&D and patent strategy
- The original patent's expiration creates opportunities for generic synthesis and new patent filings on derivatives.
- The scope of the original claims limits the use of the specific synthesis in later innovations post-expiry.
- Patent landscape shows a trend toward diversification around the core heterocyclic scaffold to extend patent protection.
Key Takeaways
- U.S. Patent 3,717,634 covers a specific chemical synthesis process for heterocyclic compounds with analgesic potential.
- Its claims focus both on the process and the compounds with defined structural parameters.
- The patent's expiration enables third-party manufacturing but the patent landscape continues to evolve through derivative patents.
- Companies research modifications to the chemical scaffolds or develop alternative synthesis pathways to bypass existing patent claims.
- The landscape demonstrates a typical lifecycle: foundational patent leading to subsequent innovation, followed by expiration and generic manufacturing.
FAQs
Q1: Can the synthesis process from Patent 3,717,634 still be used post-expiration?
A: Yes. The patent has expired, allowing anyone to use the disclosed synthesis process legally.
Q2: Are the compounds claimed in this patent still under patent protection?
A: No. The patent expired in 1991, and claims covering the compounds are now in the public domain.
Q3: How have subsequent patents built upon this patent?
A: They have expanded on the chemical structures, improved synthesis routes, or claimed novel analogs based on the core heterocyclic frameworks.
Q4: Does the patent cover all heterocyclic analgesics?
A: No. It is specific to certain heterocyclic compounds with defined structures; unrelated classes are outside its scope.
Q5: What strategic considerations should companies have regarding this patent?
A: Post-expiry, focus shifts toward developing new derivatives or novel synthetic methods to maintain competitive advantage and extend patent exclusivity.
References
[1] U.S. Patent Office. (1973). U.S. Patent No. 3,717,634. Synthesis of heterocyclic compounds.
More… ↓
⤷ Start Trial
|
